Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher

Lupin: Lupin receives USFDA nod for Paliperidone tablets that used to treat schizophrenia. The pharma company has received approval from US FDA for its Abbreviated New Drug Application (ANDA) - Paliperidone extended-release tablets. The drug is a generic equivalent of Invega extended-release tablets of Janssen Research and Development, LLC. The product will be manufactured at Lupin's facility in Goa. The drug had estimated annual sales of $152 million in the US as per IQVIA MAT March 2022 data. The drug is used in the treatement of schizophrenia, a mental disorder.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher has come out with its first quarter (April-June’ 22) earnings estimates for the Healthcare sector. The brokerage house expects Lupin to report net profit at Rs 109.5 crore down 79.8% year-on-year (down 121.1% quarter-on-quarter).

Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 59.4 percent Y-o-Y (up 66.4 percent Q-o-Q) to Rs 376.7 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.